PT - JOURNAL ARTICLE AU - Matteo Bonini AU - Marcello Di Paolo AU - Diego Bagnasco AU - Ilaria Baiardini AU - Fulvio Braido AU - Marco Caminati AU - Elisiana Carpagnano AU - Marco Contoli AU - Angelo Corsico AU - Stefano Del Giacco AU - Enrico Heffler AU - Carlo Lombardi AU - Ilaria Menichini AU - Manlio Milanese AU - Nicola Scichilone AU - Gianenrico Senna AU - Giorgio W. Canonica TI - Minimal clinically important difference for asthma endpoints: an expert consensus report AID - 10.1183/16000617.0137-2019 DP - 2020 Jun 30 TA - European Respiratory Review PG - 190137 VI - 29 IP - 156 4099 - http://err.ersjournals.com/content/29/156/190137.short 4100 - http://err.ersjournals.com/content/29/156/190137.full SO - EUROPEAN RESPIRATORY REVIEW2020 Jun 30; 29 AB - Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management.The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research.A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient reported outcomes, lung function and exercise tolerance. On the contrary, only scant and partial data are available for inflammatory biomarkers. These clearly represent the most interesting target for future development in diagnosis and clinical management of asthma, particularly in view of the several biologic drugs in the pipeline, for which regulatory agencies will soon require personalised proof of efficacy and treatment response predictors.Minimal clinically important difference (MCID) cut-offs in asthma are validated for patient reported outcomes and lung function, but not for inflammatory biomarkers. MCID represents a key target for future development in asthma management. http://bit.ly/33hcWIe